Paradigm Biopharmaceuticals Ltd.ASX: PAR

Final participant treated in Phase 2 hay fever trial

Mar 23, 2017 at 2:33 AM UTC · Issued by Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd has released a press release.

View Attachment